|March 2013 · Vol. 25, No. 3
EXAMINING THE EVIDENCE
Does desvenlafaxine alleviateYes, according to this 12-week randomized, double-blind, placebo-controlled
moderate to severe hot flashes
in a clinically meaningful way?
trial of 365 women, desvenlafaxine (100 mg daily) reduced the number of moderate
and severe hot flashes by 7.3 (62%) per day versus 4.5 (38%) per day for placebo. The severity score for women taking desvenlafaxine declined by 0.59 (25%) per day versus 0.28 (12%) per day for women taking placebo. The minimal clinically important difference—a reduction of 5.35 moderate and severe hot flashes per day—was achieved by 64% of women taking desvenlafaxine, compared with 41% of women taking placebo (P <.001).
Holly L. Thacker, MD
Director of the Center for Specialized Women’s Health, Cleveland Clinic, Cleveland, Ohio. Dr. Thacker is also Associate Professor, Department of Obstetrics and Gynecology, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, and the author of the Cleveland Clinic Guide to Menopause (Kaplan; 2009). She is Executive Director of Speaking of Women’s Health (www.speakingofwomenshealth.com; on Twitter at @SPKwomenshealth).
Untreated vasomotor symptoms (VMS) in menopausal women remain a personal, social, and economic problem. Women with untreated symptoms have a reduced ability to work and drop out of the workforce at an alarming rate.1 We know that menopausal hormone therapy (HT), the only treatment approved by the Food and Drug Administration (FDA), is the most effective therapy for VMS. However, many women cannot take HT (eg, those who have estrogen-sensitive cancer or thromboembolic disease). And since the Women’s Health Initiative, many women simply refuse HT. That leaves millions of women searching for relief, with many of them turning to unregulated and unstudied therapies.2CLICK HERE to read more